CN1512886A - 抗孕激素预防和治疗激素依赖性疾病的用途 - Google Patents

抗孕激素预防和治疗激素依赖性疾病的用途 Download PDF

Info

Publication number
CN1512886A
CN1512886A CNA018175686A CN01817568A CN1512886A CN 1512886 A CN1512886 A CN 1512886A CN A018175686 A CNA018175686 A CN A018175686A CN 01817568 A CN01817568 A CN 01817568A CN 1512886 A CN1512886 A CN 1512886A
Authority
CN
China
Prior art keywords
treatment
breast cancer
antiprogestin
hormone
antiprogestins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018175686A
Other languages
English (en)
Chinese (zh)
Inventor
延斯·霍夫曼
ϣ
罗斯玛丽·利希特纳
格哈德·西迈斯特
ε
梅尔廷·施奈德
�ˡ����˶�������˹
乌尔丽克·富尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of CN1512886A publication Critical patent/CN1512886A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA018175686A 2000-10-18 2001-10-17 抗孕激素预防和治疗激素依赖性疾病的用途 Pending CN1512886A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24099800P 2000-10-18 2000-10-18
EP00250341 2000-10-18
US60/240,998 2000-10-18
EP00250341.5 2000-10-18

Publications (1)

Publication Number Publication Date
CN1512886A true CN1512886A (zh) 2004-07-14

Family

ID=26072951

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018175686A Pending CN1512886A (zh) 2000-10-18 2001-10-17 抗孕激素预防和治疗激素依赖性疾病的用途

Country Status (26)

Country Link
US (1) US7378406B2 (https=)
EP (1) EP1328276B1 (https=)
JP (2) JP2004511522A (https=)
KR (1) KR100632908B1 (https=)
CN (1) CN1512886A (https=)
AT (1) ATE310522T1 (https=)
AU (2) AU1824302A (https=)
BG (1) BG107743A (https=)
BR (1) BR0114665A (https=)
CA (1) CA2423017C (https=)
CY (1) CY1104981T1 (https=)
CZ (1) CZ299942B6 (https=)
DE (1) DE60115274T2 (https=)
DK (1) DK1328276T3 (https=)
EE (1) EE05259B1 (https=)
ES (1) ES2253443T3 (https=)
HR (1) HRP20030387A2 (https=)
HU (1) HUP0301460A3 (https=)
IL (2) IL154975A0 (https=)
MX (1) MXPA03002954A (https=)
NO (1) NO20031740L (https=)
NZ (1) NZ538346A (https=)
PL (1) PL360151A1 (https=)
SI (1) SI1328276T1 (https=)
SK (1) SK287124B6 (https=)
WO (1) WO2002032430A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US9517240B2 (en) * 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
CN107260745A (zh) * 2010-03-22 2017-10-20 利普生物药剂公司 用于抗孕酮的非毒性递送的组合物和方法
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
EP1328276A1 (en) 2003-07-23
IL154975A0 (en) 2003-10-31
HUP0301460A3 (en) 2010-01-28
US20040048841A1 (en) 2004-03-11
CY1104981T1 (el) 2010-03-03
PL360151A1 (en) 2004-09-06
BG107743A (bg) 2004-01-30
EE05259B1 (et) 2010-02-15
DE60115274D1 (de) 2005-12-29
NZ538346A (en) 2007-03-30
HRP20030387A2 (en) 2005-04-30
KR20030044007A (ko) 2003-06-02
KR100632908B1 (ko) 2006-10-13
DE60115274T2 (de) 2006-07-27
CZ299942B6 (cs) 2008-12-29
ES2253443T3 (es) 2006-06-01
JP2010077158A (ja) 2010-04-08
NO20031740L (no) 2003-06-17
ATE310522T1 (de) 2005-12-15
NO20031740D0 (no) 2003-04-15
IL154975A (en) 2007-05-15
EE200300155A (et) 2003-08-15
US7378406B2 (en) 2008-05-27
AU2002218243B2 (en) 2006-07-13
CA2423017A1 (en) 2002-04-25
JP2004511522A (ja) 2004-04-15
AU1824302A (en) 2002-04-29
SK287124B6 (sk) 2009-12-07
SK4742003A3 (en) 2004-09-08
EP1328276B1 (en) 2005-11-23
SI1328276T1 (sl) 2006-04-30
CA2423017C (en) 2009-01-06
BR0114665A (pt) 2004-01-13
MXPA03002954A (es) 2003-08-07
WO2002032430A1 (en) 2002-04-25
HUP0301460A2 (hu) 2003-10-28
DK1328276T3 (da) 2006-04-03

Similar Documents

Publication Publication Date Title
JP2010077158A (ja) ホルモン−依存性疾病の予防及び処理のための抗黄体ホルモンの使用
AU2002218243A1 (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
CN1209111C (zh) 抗孕激素在细胞中诱导编程性细胞死亡的应用
CN1893955A (zh) 用于预防和治疗激素依赖性疾病的包含孕酮受体拮抗剂和纯抗雌激素的组合物
US20080268041A1 (en) Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
US20080261929A1 (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
HK1068098A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
ZA200303793B (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases.
US20080261933A1 (en) Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
HK1062273B (en) Use of antiprogestins for the induction of apoptosis in a cell
HK1096026A (en) Composition comprising progesterone-receptor antagonists and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068098

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1068098

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20040714

C20 Patent right or utility model deemed to be abandoned or is abandoned